CHICAGO--(BUSINESS WIRE)--CytoCore (OTCBB:CYCR) announced today that new findings based on laboratory testing of the P2X7 receptor gene indicate that this unique biomarker is capable of distinguishing between cancerous, pre-cancerous and normal tissues. The P2X7 is thereby the first biomarker to detect a cell’s potential to develop cancer.
These findings, confirming the sensitivity of the P2X7 to identify pre-malignant endometrial cancers in women, have been published in a new paper titled “Decreased Expression of P2X7 in Endometrial Epithelial Pre-Cancerous and Cancer Cells” in the journal Gynecologic Oncology, the official publication of the Society of Gynecologic Oncologists.
